Dose-comparison Study of Prednisone in Heart Failure

Phase

Condition

Chest Pain

Heart Failure

Congestive Heart Failure

Treatment

N/A

Clinical Study ID

NCT01559727

GL-2011-29

Ages 18-75
All Genders

Study Summary

The purpose of this study is to examine the efficacy of three doses of prednisone, a glucocorticoid, in treatment of patients with symptomatic heart failure.

Eligibility Criteria

Inclusion

Inclusion Criteria:

hospitalized for symptomatic heart failure
dyspnea at rest or with minimal activity
NT-proBNP > 1000pg/ml
LVEF ≤ 40%

Exclusion

Exclusion Criteria:

any condition (other than CHF) that could limit the use of prednisone;
acute decompensated heart failure
active myocarditis
obstructive or restrictive cardiomyopathy
cardiac surgery within previous 3 months
acute coronary syndrome

Study Design

March 01, 2012

March 31, 2013

Study Description

Heart failure is a leading cause of cardiovascular morbidity and mortality in the world. Most patients with acute symptomatic heart failure are admitted with fluid overload. Intravenous loop diuretics are an essential component of current treatment in such patients. Newly emerging evidence showed that glucocorticoids could potentiate natriuretic peptides' action by upregulating the expression natriuretic peptide receptor A (NPR-A) in the kidney, and produce a potent diuresis. Therefore, the investigators designed this nonblinded, randomized dose comparison study to compare the efficacy of prednisone at 15, 30 and 60 mg/day in patients with in symptomatic heart failure.

Connect with a study center

The First Hospital of Hebei Medical University
Shijiazhuang, 050031
China
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.